For the second straight year, the AACR Annual Meeting 2025 will shine a spotlight on pivotal updates that emerged from one of the world’s premier breast cancer conferences.

For 47 years, the San Antonio Breast Cancer Symposium (SABCS) has provided a forum focused on the latest breakthroughs in breast cancer and how they impact clinical care, including prevention, diagnosis, and treatment. The AACR is a proud cosponsor of the annual SABCS event, which hosted more than 11,000 breast cancer researchers, clinicians, and patient advocates in December.

“Our goal is to stimulate awareness and interest among cancer scientists on the research priorities in breast cancer,” said SABCS Codirector and AACR Past President Carlos L. Arteaga, MD, FAACR, of UT Southwestern Harold C. Simmons Comprehensive Cancer Center.

To bring the best of breast cancer translational research from the AACR Annual Meeting 2025 to SABCS 2025, the symposium plans to host a “best of AACR” session in San Antonio this year, according to SABCS program planning committee member Charles M. Perou, PhD, FAACR, of UNC Lineberger Comprehensive Cancer Center.

Added Perou, “We hope to continue to cross pollinate these impactful meetings, which each have somewhat different professional attendees. Hopefully, we can attract more AACR Annual Meeting attendees to SABCS, and encourage more SABCS attendees to go to the AACR Annual Meeting.”

The Updates from SABCS 2024 session at this year’s AACR Annual Meeting will take place this morning, 10:15-11:45 a.m. CT, in Room S103 within McCormick Place South. The session will feature four talks:

• Pedram Razavi, MD, PhD, of Memorial Sloan Kettering Cancer Center, will discuss “Multimodal integration of real-world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.”
• Avantika Gupta, PhD, of Memorial Sloan Kettering Cancer Center, will present “APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.”
• William Jacot, MD, PhD, of Montpellier Cancer Institute, will present “Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs. trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).”
• Brooke Felsheim, a graduate student in Perou’s lab at UNC Lineberger Comprehensive Cancer Center, will discuss “Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage 2-3 triple-negative breast cancer.”

For the most up-to-date information on session dates, times, and locations, check the Annual Meeting App and Online Itinerary Planner.